Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies
- PMID: 23456270
- PMCID: PMC3818570
- DOI: 10.1007/s10552-013-0174-4
Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies
Abstract
Purpose: The majority of previous studies have observed an increased risk of mucinous ovarian tumors associated with cigarette smoking, but the association with other histological types is unclear. In a large pooled analysis, we examined the risk of epithelial ovarian cancer associated with multiple measures of cigarette smoking with a focus on characterizing risks according to tumor behavior and histology.
Methods: We used data from 21 case-control studies of ovarian cancer (19,066 controls, 11,972 invasive and 2,752 borderline cases). Study-specific odds ratios (OR) and 95 % confidence intervals (CI) were obtained from logistic regression models and combined into a pooled odds ratio using a random effects model.
Results: Current cigarette smoking increased the risk of invasive mucinous (OR = 1.31; 95 % CI: 1.03-1.65) and borderline mucinous ovarian tumors (OR = 1.83; 95 % CI: 1.39-2.41), while former smoking increased the risk of borderline serous ovarian tumors (OR = 1.30; 95 % CI: 1.12-1.50). For these histological types, consistent dose-response associations were observed. No convincing associations between smoking and risk of invasive serous and endometrioid ovarian cancer were observed, while our results provided some evidence of a decreased risk of invasive clear cell ovarian cancer.
Conclusions: Our results revealed marked differences in the risk profiles of histological types of ovarian cancer with regard to cigarette smoking, although the magnitude of the observed associations was modest. Our findings, which may reflect different etiologies of the histological types, add to the fact that ovarian cancer is a heterogeneous disease.
Conflict of interest statement
Figures


Similar articles
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article. Review.
-
Interventions to reduce harm from continued tobacco use.Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005231. doi: 10.1002/14651858.CD005231.pub3. Cochrane Database Syst Rev. 2016. PMID: 27734465 Free PMC article. Review.
-
The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies.Cancer Epidemiol. 2016 Apr;41:71-9. doi: 10.1016/j.canep.2016.01.012. Epub 2016 Feb 3. Cancer Epidemiol. 2016. PMID: 26851750 Free PMC article.
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
-
Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.Cochrane Database Syst Rev. 2019 Mar 3;3(3):CD008018. doi: 10.1002/14651858.CD008018.pub3. Cochrane Database Syst Rev. 2019. PMID: 30827035 Free PMC article.
Cited by
-
Evidence-based core information for health communication of tobacco control: The effect of smoking on risks of female disease.Front Public Health. 2022 Oct 18;10:986430. doi: 10.3389/fpubh.2022.986430. eCollection 2022. Front Public Health. 2022. PMID: 36330111 Free PMC article.
-
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):443-452. doi: 10.1158/1055-9965.EPI-21-0977. Epub 2021 Nov 17. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 34789471 Free PMC article.
-
An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer.Cancers (Basel). 2020 Jun 4;12(6):1470. doi: 10.3390/cancers12061470. Cancers (Basel). 2020. PMID: 32512900 Free PMC article. Review.
-
Global epidemiology of epithelial ovarian cancer.Nat Rev Clin Oncol. 2024 May;21(5):389-400. doi: 10.1038/s41571-024-00881-3. Epub 2024 Mar 28. Nat Rev Clin Oncol. 2024. PMID: 38548868 Review.
-
Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer.Cancer Causes Control. 2020 Oct;31(10):869-879. doi: 10.1007/s10552-020-01327-8. Epub 2020 Jul 20. Cancer Causes Control. 2020. PMID: 32685996 Free PMC article.
References
-
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. - PubMed
-
- Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–1389. - PubMed
-
- Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103(3):1122–1129. - PubMed
-
- Gram IT, Lukanova A, Brill I, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer. 2012;130(9):2204–2210. - PubMed
Publication types
MeSH terms
Grants and funding
- 10124/CRUK_/Cancer Research UK/United Kingdom
- K22 CA138563/CA/NCI NIH HHS/United States
- R01 CA080742/CA/NCI NIH HHS/United States
- P50 CA105009/CA/NCI NIH HHS/United States
- C490/A10124/CRUK_/Cancer Research UK/United Kingdom
- P30 CA008748/CA/NCI NIH HHS/United States
- N01 CN55424/CN/NCI NIH HHS/United States
- R03 CA115195/CA/NCI NIH HHS/United States
- R01 CA95023/CA/NCI NIH HHS/United States
- R01 CA063682/CA/NCI NIH HHS/United States
- 10119/CRUK_/Cancer Research UK/United Kingdom
- R01 CA83918/CA/NCI NIH HHS/United States
- U01 CA069417/CA/NCI NIH HHS/United States
- N01 CN025403/CN/NCI NIH HHS/United States
- R01 CA080978/CA/NCI NIH HHS/United States
- N01 PC067010/PC/NCI NIH HHS/United States
- P30 CA016056/CA/NCI NIH HHS/United States
- R01 CA087538/CA/NCI NIH HHS/United States
- U01 CA69417/CA/NCI NIH HHS/United States
- P01 CA17054/CA/NCI NIH HHS/United States
- CA14089/CA/NCI NIH HHS/United States
- R01 CA106414/CA/NCI NIH HHS/United States
- R01 CA095023/CA/NCI NIH HHS/United States
- C490/A10119/CRUK_/Cancer Research UK/United Kingdom
- CA 8860/CA/NCI NIH HHS/United States
- R01 CA61107/CA/NCI NIH HHS/United States
- R01 CA87538/CA/NCI NIH HHS/United States
- R03 CA113148/CA/NCI NIH HHS/United States
- R01 CA058598/CA/NCI NIH HHS/United States
- R01 CA76016/CA/NCI NIH HHS/United States
- R01 CA54419/CA/NCI NIH HHS/United States
- CA92044/CA/NCI NIH HHS/United States
- R01 CA074850/CA/NCI NIH HHS/United States
- R01 CA063678/CA/NCI NIH HHS/United States
- K07 CA092044/CA/NCI NIH HHS/United States
- R01 CA16056/CA/NCI NIH HHS/United States
- P30 CA014089/CA/NCI NIH HHS/United States
- CA17054/CA/NCI NIH HHS/United States
- R01 CA083918/CA/NCI NIH HHS/United States
- R01 CA054419/CA/NCI NIH HHS/United States
- R01 CA122443/CA/NCI NIH HHS/United States
- 16561/CRUK_/Cancer Research UK/United Kingdom
- N01 PC67001/PC/NCI NIH HHS/United States
- R01 CA076016/CA/NCI NIH HHS/United States
- K07 CA143047/CA/NCI NIH HHS/United States
- CA61132/CA/NCI NIH HHS/United States
- U01 CA071966/CA/NCI NIH HHS/United States
- N01 CN25403/CN/NCI NIH HHS/United States
- P01 CA017054/CA/NCI NIH HHS/United States
- R01 CA58598/CA/NCI NIH HHS/United States
- K07 CA095666/CA/NCI NIH HHS/United States
- R01 CA112523/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
- U01 CA71966/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical